ABSTRACT
Treatment of inflammatory bowel disease (IBD) remains one of the most critical public health issues, mostly due to its wide global prevalence and dramatic impact on patients’ quality of life. One of the many mechanisms implicated in the pathogenesis of this disease appears to be attributable to gut microbiota dysbiosis. For this reason, similar to what happened for Clostridium difficile, fecal microbiota transplantation is making its way as a possible new therapeutic weapon in the treatment of this disease. In this article, we will discuss the strengths of this promising treatment, while also discussing the controversial aspects and concerns regarding one of the most innovative therapies of recent times.
